January 28, 2011 | by Actelion Pharmaceuticals Ltd
|
Reading time: 1 minute
January 28, 2011, Actelion Ltd (SIX: ATLN) and GlaxoSmithKline (GSK) today announced that clinical development of the Phase III investigational dual orexin receptor antagonist, almorexant, has been discontinued. This decision follows a review of data from additional clinical studies, which were conducted to further establish the clinical profile of almorexant, including the tolerability profile.
GSK and Actelion remain committed to conducting further research to better understand the potential of orexin receptor antagonism in sleep disorders and other indications. Both companies will continue to work on the discovery and development of new orexin receptor antagonist therapies, based on the orexin alliance formed in July 2008.
Contact
Roland Haefeli Vice President, Head of Investor Relations & Public Affairs Actelion Pharmaceuticals Ltd Gewerbestrasse 16 CH-4123 Allschwil T.: +41 61 565 62 62 F.: +1 650 624 69 36 W.: www.actelion.com
Editor's note: Image rights belong to the respective publisher.
Conclusion of this article: « Actelion and GSK Discontinue Clinical Development of Almorexant »
Source: Actelion Pharmaceuticals Ltd, Press release